Show simple item record

dc.contributor.authorCorkery, John Martin
dc.contributor.editorCalvey, Tanya
dc.date.accessioned2019-09-05T10:25:06Z
dc.date.available2019-09-05T10:25:06Z
dc.date.issued2018-01-01
dc.identifier.citationCorkery , J M 2018 , Ibogaine as a treatment for substance misuse : Potential benefits and practical dangers . in T Calvey (ed.) , Progress in Brain Research . Progress in Brain Research , vol. 242 , Elsevier B.V. , pp. 217-257 . https://doi.org/10.1016/bs.pbr.2018.08.005
dc.identifier.isbn9780128142554
dc.identifier.issn0079-6123
dc.identifier.otherPURE: 16906759
dc.identifier.otherPURE UUID: f5400803-abab-4f97-b396-fb67b6c66d9c
dc.identifier.otherScopus: 85054614025
dc.identifier.otherPubMed: 30471681
dc.identifier.urihttp://hdl.handle.net/2299/21657
dc.description.abstractIbogaine is an indole alkaloid found in the root bark of the Iboga shrub native to west Africa possessing hallucinogenic properties. For centuries it has been used in religious ceremonies and to gain spiritual enlightenment. However, since the early 1960s, its apparent ability to reduce craving for psychoactive substances including alcohol, cocaine, methamphetamine, opiates, and nicotine has led to its use in detoxification treatments. In many instances, clients receive treatment in non-medical settings, with little by way of robust scientific clinical trials. This chapter provides an overview of the potential benefits that could arise from such research. This is balanced against the serious adverse effects that can occur due to undiagnosed health conditions and/or concomitant use of other drugs. A detailed update is provided of the 33 deaths known to have occurred, including 5 in the UK. Looking forward, there is a need to develop better opiate detoxification treatment against a background of increasing opioid-related fatalities. A congener of ibogaine, 18-MC, appears to be safer and is to undergo clinical trials. In the meantime, would-be consumers and treatment providers must make more careful, detailed risk-assessments before using ibogaine. Treatment outcomes, including deaths, need to be accurately recorded and published.en
dc.format.extent41
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofProgress in Brain Research
dc.relation.ispartofseriesProgress in Brain Research
dc.subjectCure/remedy
dc.subjectDeaths/fatalities
dc.subjectIbogaine/iboga
dc.subjectOpiate/opioid addiction
dc.subjectTreatment
dc.subjectUK
dc.subjectNeuroscience(all)
dc.titleIbogaine as a treatment for substance misuse : Potential benefits and practical dangersen
dc.contributor.institutionPsychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit
dc.contributor.institutionDepartment of Pharmacy, Pharmacology and Postgraduate Medicine
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85054614025&partnerID=8YFLogxK
dcterms.dateAccepted2018-01-01
rioxxterms.versionP
rioxxterms.versionofrecordhttps://doi.org/10.1016/bs.pbr.2018.08.005
rioxxterms.typeOther


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record